Metabolic tumor volume on ¹⁸F-fluorodeoxyglucose uptake as prognostic marker for osimertinib in patients with non-small cell lung cancer harboring sensitive EGFR mutation.

ABSTRACT:

Background

Fluorine-18 fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography (PET) is a useful modality for the diagnosis of various cancers; however, its role in predicting the therapeutic response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) remains unclear. The effect of metabolic tumor activity on ¹⁸F-FDG accumulation was analyzed to evaluate the efficacy of osimertinib monotherapy in patients with non-small cell lung cancer (NSCLC) harboring activating EGFR mutations.

Methods

Sixty-eight patients who underwent ¹⁸F-FDG PET prior to osimertinib initiation were enrolled in this study. The maximum and peak standardized uptake values (SUV_max and SUV_peak), metabolic tumor volume

SUBMITTER: Hashimoto K 

PROVIDER: S-EPMC12775706 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature